Annovis BioANVS
ANVS
About: Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Employees: 6
0
Funds holding %
of 7,431 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
23% more call options, than puts
Call options by funds: $182K | Put options by funds: $148K
14% more capital invested
Capital invested by funds: $3.13M [Q1] → $3.57M (+$445K) [Q2]
2.25% less ownership
Funds ownership: 10.71% [Q1] → 8.46% (-2.25%) [Q2]
7% less funds holding
Funds holding: 44 [Q1] → 41 (-3) [Q2]
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$12
384%
upside
Avg. target
$12
384%
upside
High target
$12
384%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 384%upside $12 | Buy Maintained | 9 Jun 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and second quarter 2025 financial results.
Neutral
GlobeNewsWire
2 weeks ago
Annovis Completes Full Patent Transfer to Crystal Buntanetap
Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new crystalline forms of buntanetap. Both forms are covered by a total of 13 patent families.
Neutral
GlobeNewsWire
2 months ago
Annovis to Attend the AAIC 2025 with Four Poster Presentations
MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer's Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada.
Neutral
GlobeNewsWire
2 months ago
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance
MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it received notification (the "Acceptance Letter") from the New York Stock Exchange ("NYSE") that the NYSE has accepted the Company's previously-submitted plan (the "Plan") to regain compliance with the NYSE's continued listing standards relating to minimum market capitalization and stockholders' equity.
Positive
Zacks Investment Research
2 months ago
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy
Annovis Bio (ANVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
2 months ago
Annovis to Host Webinar and Live Q&A on June 24, 2025
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a live webcast where Maria Maccecchini, Ph.D., President and CEO, will provide updates and answer questions from the audience.
Neutral
GlobeNewsWire
3 months ago
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results
Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and first quarter 2025 financial results.
Neutral
GlobeNewsWire
3 months ago
Annovis Bio Appoints Hui Liu as Director of Biostatistics
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment Hui Liu as Director of Biostatistics.
Neutral
GlobeNewsWire
4 months ago
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on March 26, 2025, it received notice (the “Notice”) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders' equity was less than $50 million.
Neutral
GlobeNewsWire
5 months ago
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its participation in the AD/PD™ 2025 taking place April 1-5 in Vienna.
Charts implemented using Lightweight Charts™